News

Sagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567
Sagimet Biosciences' FASN inhibitors show promise in acne and metabolic disease. Read my analysis on SGMT stock and see why I ...
Pharmaceutical Technology on MSN1d
Ascletis’s daily acne tablet set for China review after Phase III win
The Phase III trial, conducted by Chinese license partner Ascletis, produced strong results for denifanstat compared to ...
Sagimet climbs as acne therapy hits main goals in late-stage trial in China
Sagimet Biosciences (NASDAQ:SGMT) added ~38% in the premarket on Wednesday after the company said its Chinese licensing ...
Fierce Biotech1d
Ascletis scores phase 3 win for daily acne pill, prepares push to Chinese regulators
Ascletis Pharma’s acne pill has scored a phase 3 win, leading the Chinese biotech to claim the Sagimet Biosciences-sourced ...
Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that denifanstat (ASC40), a first-in-class, once-daily oral small molecule fatty acid synthase (FASN) inhibitor, meets all primary, key ...